Ankle cartilage repair therapy trial halted early
NCT ID NCT02537067
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a treatment called Chondron, made from a patient's own cartilage cells, for repairing ankle cartilage defects. The trial aimed to see if the treatment could improve cartilage quality and ankle function over 18 months. However, the study was terminated early and included only 28 people, so the findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Chondron (autologous cultured chondrocytes)
- What this could lead to
- If successful, this could provide a way to repair ankle cartilage damage, potentially reducing pain and improving joint function.
- What could go wrong
- The trial was terminated early with only 28 participants, so results are limited. Cartilage repair may not last or may require additional surgeries.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANKLE (LIGAMENTS); INSTABILITY, FAMILIAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Eulji General Hospital
Seoul, Seoul, South Korea
-
Myongji Hospital
Goyang-si, Gyeonggi-do, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.